18 May 2023
Diaceutics PLC
("Diaceutics" or "the Company")
Results of Annual General Meeting
Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed.
The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website www.diaceutics.com
| Resolution | For (excluding at Chair's discretion) | Against | Total votes cast | Withheld | |||
|
|
| Number of votes | %* | Number of votes | %* |
| Number of votes |
| 1 | Ordinary resolution to receive and consider the 2022 Financial Statements | 60,055,552 | 100.00% | 0 | 0.00% | 60,055,552 |
Nil
|
| 2 | Ordinary resolution to approve the directors' remuneration report | 51,885,466 | 89.43% | 6,131,086 | 10.57% | 60,055,552 |
2,039,000 |
| 3 | Ordinary resolution to re-elect Peter Keeling as a director | 59,406,925 | 98.92% | 648,627 | 1.08% | 60,055,552 | Nil |
| 4 | Ordinary resolution to re-elect Michael Wort as a director | 55,788,593 | 92.89% | 4,266,959 | 7.11% | 60,055,552 | Nil |
| 5 | Ordinary resolution to re-appoint Ernst & Young as auditors | 60,055,552 | 100.00% | 0 | 0.00% | 60,055,552 |
Nil |
| 6 | Ordinary resolution to authorise the directors to determine the remuneration of the auditors |
60,055,552 | 100.00% | 0 | 0.00% | 60,055,552 |
Nil
|
| 7 | Ordinary resolution to authorise the directors to allot shares |
60,055,552 | 100.00% | 0 | 0.00% | 60,055,552 |
Nil
|
| 8 | Special resolution to authorise the directors to disapply pre-emption rights |
60,055,202 | 99.9% | 350 | 0.01% | 60,055,552 |
Nil |
| 9 | Special resolution to authorise the directors to purchase own shares | 59,976,122 | 100.00% | 0 | 0.00% | 60,055,552 |
79,430 |
*Percentage of votes cast excludes withheld votes
Enquiries:
| Diaceutics PLC | |
| Peter Keeling, Chief Executive Officer | Via Alma PR |
| Nick Roberts, Chief Financial Officer | |
| | |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison, Nick Harland, Nick Adams | |
| | |
| Alma PR | Tel: +44(0)20 3405 0205 |
| Caroline Forde, Kieran Breheny, Matthew Young, Kinvara Verdon | diaceutics@almapr.co.uk |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real‐world healthcare data insights, advisory services and innovative platform enabled solutions.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
